2. INFLAMACION Y ENFERMEDAD CARDIOVASCULAR

12. MICROBIOMA HUMANO Y ENFERMEDAD CARDIOVASCULAR

19. LDL Y ENFERMEDAD CARDIOVASCULAR: MÁS ALLÁ DE LAS ESTATINAS

44. HDL Y ENFERMEDAD CARDIOVASCULAR

53. HDL and Cardiovascular-Disease Risk — Time for a New Approach? N Engl J Med 2011; 364:170-171 January 13, 2011 Editorial Jay Heinecke, M.D.

54. Clinical Implications of Basic Research Sorting Out Cholesterol and Coronary Artery Disease Patrick Linsel-Nitschke, M.D., Nilesh J. Samani, M.D., M.B., Ch.B., and Heribert Schunkert, M.D. N Engl J Med 2010; 363:2462-2463

55. Sortilin 1 and the Risk of Coronary Disease. Linsel-Nitschke P et al. N Engl J Med 2010;363:2462-2463.

56. Original Article Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease Christopher P. Cannon, M.D., Sukrut Shah, Ph.D., R.Ph., Hayes M. Dansky, M.D., Michael Davidson, M.D., Eliot A. Brinton, M.D., Antonio M. Gotto, Jr., M.D., D.Phil., Michael Stepanavage, M.S., Sherry Xueyu Liu, M.S., Patrice Gibbons, M.S., Tanya B. Ashraf, B.A., Jennifer Zafarino, M.S., Yale Mitchel, M.D., Philip Barter, M.D., Ph.D., for the DEFINE Investigators N Engl J Med Volume 363(25):2406-2415 December 16, 2010

57. Study Overview In this trial, anacetrapib, a cholesteryl ester transfer protein inhibitor, was shown to reduce LDL cholesterol by 40% in patients receiving maximal statin therapy and to increase HDL cholesterol by 138%, as compared with placebo.

58. Changes in Cholesterol Levels and Blood Pressure during the Study Period. Cannon CP et al. N Engl J Med 2010;363:2406-2415

59. Conclusions Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib.

60. EPIGENÉTICA Y ENFERMEDAD CARDIOVASCULAR

65. INSULINORESISTENCIA Y ENFERMEDAD CARDIOVASCULAR

66. Effects of Thiazolidinediones. Kahn BB, McGraw TE. N Engl J Med 2010;363:2667-2669.

67. A Comparison of PPARγ Activity in Lean and Obese Persons. Kahn BB, McGraw TE. N Engl J Med 2010;363:2667-2669.

68. NUTRICIÓN Y ENFERMEDAD CARDIOVASCULAR

71. REPROGRAMACIÓN CELULAR Y ENFERMEDAD CARDIOVASCULAR

72. Clinical Implications of Basic Research Reprogramming Fibroblasts into Cardiomyocytes Charles E. Murry, M.D., Ph.D., and William T. Pu, M.D. N Engl J Med 2011; 364:177-17

73. The Path from Fibroblast to Cardiomyocyte. Murry CE, Pu WT. N Engl J Med 2011;364:177-178.

93. LA POBREZA Y ENFERMEDAD CARDIOVASCULAR